Markets:

Overview

News

Currencies

International

Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

4.950 +0.040 (+0.81%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

What's Going On With Candel Therapeutics Stock On Friday? ↗

April 05, 2024

Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for non-metastatic prostate cancer. Exciting developments continue with updated...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 05, 2024

Via Benzinga

Unusually High Volume Points to Upside in These Stocks

April 05, 2024

Unusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance.

Via MarketBeat

Topics ETFs

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

April 05, 2024

It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!

Via InvestorPlace

Recap: Candel Therapeutics Q4 Earnings ↗

March 28, 2024

Via Benzinga

Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies

February 15, 2024

--News Direct--

Via News Direct

Ford, Candel Therapeutics, Nvidia, Palantir, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

April 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 04, 2024

Via Benzinga

Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results ↗

April 04, 2024

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 04, 2024

Via Benzinga

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 04, 2024

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%...

Via Benzinga

Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings ↗

April 04, 2024

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P...

Via Benzinga

Topics Stocks

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study ↗

April 04, 2024

Candel Therapeutics updates phase 2 trial results for CAN-2409 and valacyclovir in pancreatic cancer treatment, revealing prolonged survival rates up to 28.8 months versus standard therapy's 12.5...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 04, 2024

Via Benzinga

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

April 04, 2024

From Candel Therapeutics

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 04, 2024

We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!

Via InvestorPlace

Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy ↗

April 01, 2024

Data from Candel Therapeutics on CAN-3110, a promising viral immunotherapy for recurrent high-grade glioma. Discover survival rates and potential advancements in cancer treatment.

Via Benzinga

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

March 28, 2024

From Candel Therapeutics

Via GlobeNewswire

CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023 ↗

March 28, 2024

CADL stock results show that Candel Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

March 28, 2024

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

March 15, 2024

--News Direct--

Via News Direct

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

March 06, 2024

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

Via FinancialNewsMedia

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

March 05, 2024

From Candel Therapeutics

Via GlobeNewswire

Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

February 28, 2024

--News Direct--

Via News Direct

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 13, 2024

Via Benzinga

Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies ↗

February 13, 2024

A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion.

Via Benzinga

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

February 13, 2024

From Candel Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 05, 2024

Via Benzinga

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

February 05, 2024

From Candel Therapeutics

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 18, 2023

It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.